Ebola Vaccine Ring Vaccination Trial in Guinea

Conditions

Ebola Virus Disease

Simon JK, Kennedy SB, Mahon BE, Dubey SA, Grant-Klein RJ, Liu K, Hartzel J, Coller BG, Welebob C, Hanson ME, Grais RF.

2022-10-0516 citations

10.1016/j.vaccine.2022.09.037

Factors influencing participation in an Ebola vaccine trial among front-line workers in Guinea

Kyra H. Grantz, Pauline Claudot, Micky Kambala, Mariama Kouyaté, Aboubacar Soumah et al. (10 authors)

Vaccine2019-10-1424 citations

10.1016/j.vaccine.2019.09.094

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).

Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Gsell PS, Hossmann S, Watle SV, Kondé MK, Kéïta S, Kone S, Kuisma E, Levine MM, Mandal S, Mauget T, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Røttingen JA, Kieny MP.

2016-12-23754 citations

10.1016/s0140-6736(16)32621-6

Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.

Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Carroll MW, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Hossmann S, Kondé MK, Kone S, Kuisma E, Levine MM, Mandal S, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Watson CH, Kéïta S, Kieny MP, Røttingen JA.

2015-08-03523 citations

10.1016/s0140-6736(15)61117-5

Interventions

rVSV-ZEBOV Ebola Vaccine Immediate

rVSV-ZEBOV Ebola Vaccine Delayed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Individuals aged 18 years or older who live in the defined vaccination ring Children 6 to 17 years following results from phase 2 study in Gabon, and following DSMB recommendation (3 July 2015)

Exclusion criteria

Exclusion criteria: History of EVD (self-report or laboratory confirmed). Pregnancy (verbal report) or breast-feeding. Women will be offered, but not required to take, a pregnancy test. History of having received other investigational research agents in the previous 28 days. Self- report of clinically important immunodeficiency condition, e.g. HIV/AIDS. History of anaphylaxis to a vaccine or vaccine component Severe illness that makes the person bed-bound or requiring hospitalization at the time of the vaccination.

Design outcomes

Primary

Measure	Time frame
Any probable or supsected case from which a blood sample taken is laboratory confirmed as positive for EVD, or any deceased individual with probable EVD, from which a post-mortem sample taken within 48 hours after death is laboratory confirmed as positive for Ebola Virus Disease	—

Secondary

Measure	Time frame
Incidense of Serious Adverse Events	—

Countries

Guinea

Contacts

Public ContactMandy Kader Konde

Ministry of Health and Hygiene Guinea

kaderkonde@ceforpag.org+224 622 40 86 48

Outcome results

None listed